
The Library
Negative feedback regulation of the ERK1/2 MAPK pathway
Tools
Lake, David, Corrêa, Sônia A. L. and Müller, Jürgen (2016) Negative feedback regulation of the ERK1/2 MAPK pathway. Cellular and molecular life sciences : CMLS, 73 (23). 4397. doi:10.1007/s00018-016-2297-8 ISSN 1420-9071.
![]() |
PDF
WRAP_3A10.1007%2Fs00018-016-2297-8.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (1251Kb) |
Official URL: http://dx.doi.org/10.1007/s00018-016-2297-8
Abstract
The extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK) signalling pathway regulates many cellular functions, including proliferation, differentiation, and transformation. To reliably convert external stimuli into specific cellular responses and to adapt to environmental circumstances, the pathway must be integrated into the overall signalling activity of the cell. Multiple mechanisms have evolved to perform this role. In this review, we will focus on negative feedback mechanisms and examine how they shape ERK1/2 MAPK signalling. We will first discuss the extensive number of negative feedback loops targeting the different components of the ERK1/2 MAPK cascade, specifically the direct posttranslational modification of pathway components by downstream protein kinases and the induction of de novo gene synthesis of specific pathway inhibitors. We will then evaluate how negative feedback modulates the spatiotemporal signalling dynamics of the ERK1/2 pathway regarding signalling amplitude and duration as well as subcellular localisation. Aberrant ERK1/2 activation results in deregulated proliferation and malignant transformation in model systems and is commonly observed in human tumours. Inhibition of the ERK1/2 pathway thus represents an attractive target for the treatment of malignant tumours with increased ERK1/2 activity. We will, therefore, discuss the effect of ERK1/2 MAPK feedback regulation on cancer treatment and how it contributes to reduced clinical efficacy of therapeutic agents and the development of drug resistance.
Item Type: | Journal Article | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Subjects: | Q Science > QH Natural history Q Science > QP Physiology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
||||||||||
Divisions: | Faculty of Science, Engineering and Medicine > Science > Life Sciences (2010- ) Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||||||
SWORD Depositor: | Library Publications Router | ||||||||||
Library of Congress Subject Headings (LCSH): | Mitogen-activated protein kinases , Tumors | ||||||||||
Journal or Publication Title: | Cellular and molecular life sciences : CMLS | ||||||||||
Publisher: | Springer | ||||||||||
ISSN: | 1420-9071 | ||||||||||
Official Date: | 1 December 2016 | ||||||||||
Dates: |
|
||||||||||
Volume: | 73 | ||||||||||
Number: | 23 | ||||||||||
Article Number: | 4397 | ||||||||||
DOI: | 10.1007/s00018-016-2297-8 | ||||||||||
Status: | Peer Reviewed | ||||||||||
Publication Status: | Published | ||||||||||
Access rights to Published version: | Open Access (Creative Commons) | ||||||||||
Date of first compliant deposit: | 27 February 2017 | ||||||||||
Date of first compliant Open Access: | 27 February 2017 |
Request changes or add full text files to a record
Repository staff actions (login required)
![]() |
View Item |
Downloads
Downloads per month over past year